文献速递肝病消化道肿瘤与早癌

无干扰素直接抗病毒药物治愈与丙肝相关肝癌患者生存率提高相关:东西方数据

Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West.
PubMed 文献 · Hepatology · 2020-05-08

该多国 consortium 研究纳入 2005-2017 年美国和亚洲 8 个中心的 1676 例 HCV 相关 HCC 患者,比较未治疗 HCV 者与 DAA 治疗获 SVR 者的生存。经倾向评分匹配和时间变化 Cox 回归,SVR 组 5 年总生存率显著更高(87.78% vs 66.05%),全因死亡风险降低 63%,肝相关死亡风险降低 66%。

要点

  • HCV 相关 HCC 患者获得 SVR 与 5 年全因死亡风险降低 63% 独立相关。
  • SVR 组 5 年总生存率 87.78%,未治疗组 66.05%。
  • 适合 HCC 治疗的患者也应考虑 DAA 治疗。

核心结论

  • HCV 相关 HCC 患者获得 SVR 后 5 年全因和肝相关生存率较未治疗 HCV 者提高 60%-70%。

研究设计与样本

  • 多国 consortium 研究,使用 2005-2017 年美国 2 个和亚洲 6 个中心数据,纳入 1676 例 HCV 单感染相关 HCC 患者。
  • 患者分为未治疗 HCV 组(1239 例)和 DAA 治疗获 SVR 组(437 例),采用倾向评分匹配,多变量 Cox 回归以 HCV 治疗状态为时间变化协变量,并进行 landmark 分析。

主要发现

  • 倾向评分匹配后 321 对患者基线风险均衡(所有 P > 0.05)。
  • 时间变化调整后,SVR 组 5 年总生存率显著高于未治疗组(87.78% vs 66.05%,P < 0.001)。
  • 多变量 Cox 回归显示 SVR 与 5 年全因死亡风险降低 63% 独立相关(HR 0.37,95%CI 0.16-0.83,P = 0.016)。
  • SVR 与 5 年肝相关死亡风险降低 66% 独立相关(HR 0.34,95%CI 0.13-0.88,P = 0.026)。
  • 90、180、360 天 landmark 分析结果一致(HR 范围 0.22-0.44,所有 P < 0.05)。

临床怎么用

  • HCV 相关 HCC 患者若适合 HCC 治疗,也应考虑接受 DAA 治疗以争取 SVR。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Survival data among patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) after achieving sustained virologic response (SVR) with interferon-free direct-acting antivirals (DAAs) in both Asian and western countries are limited. Survival rates were compared between patients with HCV-related HCC who were untreated for HCV and those who achieved SVR. APPROACH AND RESULTS: Using data from two U.S. and six Asian centers from 2005 to 2017, we categorized 1,676 patients who were mono-infected with HCV-related HCC into patients untreated for HCV (untreated group) and DAA-treated patients with SVR (SVR group) and matched by propensity score matching (PSM); multivariable Cox regression with HCV treatment status as a time-varying covariate was used to determine mortality risk and landmark analysis to avoid immortal time bias. There were 1,239 untreated patients and 437 patients with SVR. After PSM, background risks of the 321 pairs of matched patients were balanced (all P > 0.05). After time-varying adjustment for HCV treatment initiation compared with untreated patients, patients with SVR had significantly higher 5-year overall survival (87.78% vs. 66.05%, P < 0.001). Multivariable Cox regression showed that SVR was independently associated with a 63% lower risk of 5-year all-cause mortality (hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.16-0.83; P = 0.016) and 66% lower risk of 5-year liver-related mortality (HR, 0.34; 95% CI, 0.13-0.88; P = 0.026) with similar trends after removing patients with liver transplants. Landmark analysis at 90, 180, and 360 days showed consistent results (HRs ranged 0.22 to 0.44, all P < 0.05). CONCLUSION: In this multinational consortium, patients with HCV-related HCC who obtained SVR achieved a 60%-70% improvement in 5-year survival (both all-cause and liver related) compared with patients untreated for HCV. Patients eligible for HCC therapy should also be considered for DAA therapy.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Dang H, Yeo YH, Yasuda S, et al. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. Hepatology. 2020. PMID: 31610027. doi:10.1002/hep.30988

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。